Profound Medical honored with INOVAIT's 2025–2026 Mount Logan Award for the TULSA Procedure

Profound Medical received INOVAIT's 2025–2026 Mount Logan Award recognizing its TULSA Procedure, the article reports. The article describes TULSA as an incision- and radiation-free, MRI-guided transurethral ultrasound treatment that the company says is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA.

Profound Medical was honored with INOVAIT's 2025–2026 Mount Logan Award for its TULSA Procedure, the article reports. The article describes Profound as a commercial-stage medical device company that develops and markets iMRI procedures. The TULSA Procedure is described as combining real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The company describes the treatment as an incision- and radiation-free, single-session procedure performed under MR guidance to target prostate tissue. Key facts: - INOVAIT named the TULSA Procedure for the 2025–2026 Mount Logan Award, according to the article. - The TULSA-PRO system is described as combining real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. - The article notes the procedure is performed in a single session without incisions or radiation and is reported to heat targeted tissue to about 55–57°C while using MR guidance to preserve urinary continence and sexual function. - The article states there is no bleeding associated with the procedure, no hospital stay is required, and most patients report a quick recovery to normal routine. - The TULSA-PRO system is reported as CE marked, approved by Health Canada, and 510(k) cleared by the U.S. Food and Drug Administration. Summary: The INOVAIT award brought external recognition to the TULSA Procedure as described in the article. Undetermined at this time.